Logo image of BIO3.DE

BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) Stock Fundamental Analysis

FRA:BIO3 - Deutsche Boerse Ag - DE0005227235 - Currency: EUR

30  0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to BIO3. BIO3 was compared to 68 industry peers in the Biotechnology industry. BIO3 has an average financial health and profitability rating. BIO3 has a valuation in line with the averages, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

BIO3 had negative earnings in the past year.
In the past year BIO3 had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: BIO3 reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: BIO3 reported negative operating cash flow in multiple years.
BIO3.DE Yearly Net Income VS EBIT VS OCF VS FCFBIO3.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

1.2 Ratios

BIO3 has a Return On Assets of -1.73%. This is in the better half of the industry: BIO3 outperforms 68.49% of its industry peers.
BIO3 has a better Return On Equity (-4.81%) than 69.86% of its industry peers.
BIO3 has a better Return On Invested Capital (0.54%) than 76.71% of its industry peers.
Industry RankSector Rank
ROA -1.73%
ROE -4.81%
ROIC 0.54%
ROA(3y)2.71%
ROA(5y)-0.12%
ROE(3y)7.23%
ROE(5y)-0.54%
ROIC(3y)N/A
ROIC(5y)N/A
BIO3.DE Yearly ROA, ROE, ROICBIO3.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20 30

1.3 Margins

BIO3 has a Operating Margin of 1.87%. This is in the better half of the industry: BIO3 outperforms 76.71% of its industry peers.
In the last couple of years the Operating Margin of BIO3 has grown nicely.
BIO3's Gross Margin of 23.19% is in line compared to the rest of the industry. BIO3 outperforms 53.42% of its industry peers.
BIO3's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 1.87%
PM (TTM) N/A
GM 23.19%
OM growth 3YN/A
OM growth 5Y99.04%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y25.34%
GM growth 5Y0.06%
BIO3.DE Yearly Profit, Operating, Gross MarginsBIO3.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40

More info and screens

5

2. Health

2.1 Basic Checks

BIO3 has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
BIO3 has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, BIO3 has about the same amount of shares outstanding.
The debt/assets ratio for BIO3 has been reduced compared to a year ago.
BIO3.DE Yearly Shares OutstandingBIO3.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
BIO3.DE Yearly Total Debt VS Total AssetsBIO3.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

2.2 Solvency

An Altman-Z score of 2.04 indicates that BIO3 is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.04, BIO3 is doing good in the industry, outperforming 65.75% of the companies in the same industry.
BIO3 has a debt to FCF ratio of 46.44. This is a negative value and a sign of low solvency as BIO3 would need 46.44 years to pay back of all of its debts.
BIO3 has a better Debt to FCF ratio (46.44) than 78.08% of its industry peers.
A Debt/Equity ratio of 1.26 is on the high side and indicates that BIO3 has dependencies on debt financing.
BIO3 has a Debt to Equity ratio of 1.26. This is in the lower half of the industry: BIO3 underperforms 60.27% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF 46.44
Altman-Z 2.04
ROIC/WACC0.09
WACC5.93%
BIO3.DE Yearly LT Debt VS Equity VS FCFBIO3.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

BIO3 has a Current Ratio of 4.93. This indicates that BIO3 is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 4.93, BIO3 is doing good in the industry, outperforming 79.45% of the companies in the same industry.
A Quick Ratio of 1.66 indicates that BIO3 should not have too much problems paying its short term obligations.
BIO3 has a Quick ratio (1.66) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.93
Quick Ratio 1.66
BIO3.DE Yearly Current Assets VS Current LiabilitesBIO3.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for BIO3 have decreased strongly by -117.24% in the last year.
Looking at the last year, BIO3 shows a very negative growth in Revenue. The Revenue has decreased by -15.85% in the last year.
Measured over the past years, BIO3 shows a quite strong growth in Revenue. The Revenue has been growing by 11.62% on average per year.
EPS 1Y (TTM)-117.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-173.33%
Revenue 1Y (TTM)-15.85%
Revenue growth 3Y12.09%
Revenue growth 5Y11.62%
Sales Q2Q%-42.29%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y1600%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.95%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BIO3.DE Yearly Revenue VS EstimatesBIO3.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
BIO3.DE Yearly EPS VS EstimatesBIO3.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2020 2021 2022 2024 2025 0 1 -1

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BIO3. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 19.80, which indicates a rather expensive current valuation of BIO3.
Compared to the rest of the industry, the Price/Forward Earnings ratio of BIO3 indicates a rather cheap valuation: BIO3 is cheaper than 86.30% of the companies listed in the same industry.
BIO3 is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 35.19, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 19.8
BIO3.DE Price Earnings VS Forward Price EarningsBIO3.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, BIO3 is valued a bit cheaper than the industry average as 75.34% of the companies are valued more expensively.
79.45% of the companies in the same industry are more expensive than BIO3, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 82.44
EV/EBITDA 33.87
BIO3.DE Per share dataBIO3.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

BIO3's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

4

5. Dividend

5.1 Amount

With a yearly dividend of 0.09%, BIO3 is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 14.54, BIO3 pays a better dividend. On top of this BIO3 pays more dividend than 90.41% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.35, BIO3's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.09%

5.2 History

On average, the dividend of BIO3 grows each year by 14.87%, which is quite nice.
Dividend Growth(5Y)14.87%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

BIO3's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
BIO3.DE Yearly Income VS Free CF VS DividendBIO3.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

More info and screens

BIOTEST AG-VORZUGSAKTIEN

FRA:BIO3 (5/23/2025, 1:53:46 PM)

30

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12
Earnings (Next)08-04 2025-08-04
Inst Owners0.21%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.19B
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.09%
Yearly Dividend0.04
Dividend Growth(5Y)14.87%
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 19.8
P/S 1.87
P/FCF 82.44
P/OCF 82.44
P/B 2.33
P/tB 2.41
EV/EBITDA 33.87
EPS(TTM)-0.65
EYN/A
EPS(NY)1.52
Fwd EY5.05%
FCF(TTM)0.36
FCFY1.21%
OCF(TTM)0.36
OCFY1.21%
SpS16.05
BVpS12.88
TBVpS12.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.73%
ROE -4.81%
ROCE 0.95%
ROIC 0.54%
ROICexc 0.56%
ROICexgc 0.57%
OM 1.87%
PM (TTM) N/A
GM 23.19%
FCFM 2.27%
ROA(3y)2.71%
ROA(5y)-0.12%
ROE(3y)7.23%
ROE(5y)-0.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y111.24%
ROICexc growth 3YN/A
ROICexc growth 5Y111.29%
OM growth 3YN/A
OM growth 5Y99.04%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y25.34%
GM growth 5Y0.06%
F-Score3
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 1.26
Debt/FCF 46.44
Debt/EBITDA 12.19
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 0.82
Cash Conversion 27.43%
Profit Quality N/A
Current Ratio 4.93
Quick Ratio 1.66
Altman-Z 2.04
F-Score3
WACC5.93%
ROIC/WACC0.09
Cap/Depr(3y)81.86%
Cap/Depr(5y)79.06%
Cap/Sales(3y)4.84%
Cap/Sales(5y)4.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-117.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-173.33%
EPS Next Y1600%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-15.85%
Revenue growth 3Y12.09%
Revenue growth 5Y11.62%
Sales Q2Q%-42.29%
Revenue Next Year11.95%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-93.3%
EBIT growth 3YN/A
EBIT growth 5Y122.17%
EBIT Next Year825%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y114.72%
FCF growth 3Y27.05%
FCF growth 5YN/A
OCF growth 1Y114.72%
OCF growth 3Y21.56%
OCF growth 5YN/A